A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
The purpose of this study is to assess the safety and effectiveness of the investigational drug abemaciclib in patients with hormone receptor-positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain or spinal fluid. Abemaciclib is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. Abemaciclib is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients in this study must have breast cancer that is estrogen or progesterone receptor-positive and has spread to the brain; NSCLC or melanoma that has caused brain metastases that need to be surgically removed; or hormone receptor-positive breast cancer, NSCLC, or melanoma that has spread to the spinal fluid.
- With the exception of certain concurrent therapies, patients must have completed prior treatments at least 2 weeks before entering the study.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Mariza Daras at 212-610-0239.